1. Home / Research and Publications

Our doctors don’t just treat renal diseases, they actively work to find ways to treat and prevent it through ongoing research and clinical trials.  

Take a look at some of the studies and publications that our kidney specialists have contributed to and conducted.

Clinical Trials and Publications

Jayant Kumar, M.D. leads an active clinical research program at RMA. Below is a list of research publications.

  • Amgen 20050182 “EVOLVE” study, enrollment starting 2006, completed 
  • ALTITUDE trial, Randomized trial to look at benefit of Aliskiren as add on therapy in diabetic nephropathy, Novartis, Renal Medicine Associates: 07/2009 – 07/2013 
  • ACCESS: Randomized, double-blinded, parallel group, multicenter study to evaluate efficacy of HX575 epoetin alpha vs Procrit in anemia with kidney disease. 04/2013 till date. Sandoz.  Completed, largest site in the US.  
  • AKB-6548-CI-0007, Phase 2b Randomized, Double-Blind, Placebo controlled study to assess AKB-6548 in subjects with anemia and CKD. Akebia. completed 
  • M11-352, Abbvie. Phase 3 study, diabetic nephropathy. Active, One of 12 High Potential sites in US. completed 
  • B1261007, Pfizer. Phase 2 study, Diabetic Nephropathy, completed 
  • Fibrogen 60, 63, 64. HIF in Anemia with CKD and ESRD, Phase 3, completed 
  • TREVI 01 and 02, Nalbuphine for uremic pruritis in ESRD, TREVI, completed 
  • 28431754DNE3001/ CREDENCE 
  • A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy, completed 
  • JNJ-28431754. A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2, completed 
  • Diabetes Mellitus and Diabetic Nephropathy The CREDENCETM Trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial). Completed 
  • CV185-450. RENaL hemoldialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF) 
  • CR845-CLIN3102/3103. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravenous
  • CR845 in Hemodialysis Patients with moderate-to-severe Pruritus, with a 52-Week Open-label Extension. Completed 
  • AKB-6548/CI 014/015/016/017. Phase 3, Randomized, OPEN-LABEL, ACTIVE-Controlled Study EVALUATING the Efficacy and Safety of Oral AKB-6548 FOR THE CORRECTION OF Anemia IN SUBJECTS WITH DIALYSIS and NON-DIALYSIS-Dependent Chronic Kidney Disease (nDD-CKD). completed 
  • P-Monofer-IDA/CKD-EXT01 and 04. A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease, P-Monofer-CKD-04. completed 
  • NN9535-4312. Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease. Ongoing 
  • AZD 7442-D8850C00002. A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19. Ongoing 
  • 404-201-00012/Otsuka. Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting from Erythropoiesis-Stimulating Agents (ESAs). Ongoing 
  • ID-080A301. Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with resistant hypertension (RHT). Ongoing 

Publications

As thought leaders and researchers in chronic kidney disease, our renal physicians frequently participate in conferences and peer-related events. View their upcoming events and take a look at their previous articles and presentations.

Elizabeth Evans, DNP

Elizabeth Evans, DNP passion for academic medicine and education. She wrote a chapter in Hypertension in Brunner & Suddarth Textbook of Medical-Surgical Nursing 2021. 

Elizabeth recently completed a chapter in Contemporary Nephrology Nursing Textbook on Anemia to be published later in 2022. Her previous published data is available at the online Library of American Nephrology Nurses Association. 

Stephanie Mahooty, DNP

Stephanie Mahooty, DNP published a short article in the March 2022 Issue of American Society of Nephrology Kidney News on Promoting Kidney Health Among American Indians and Alaskan Natives

Fidel Barrantes, MD

Fidel Barrantes, M.D. works with colleagues and professionals and presented in national professional society meetings. Below is a summary of his work in the past 7 years.

Timothy Muchayi MD

  • Minimal change disease after hematopoietic stem cell transplant: Manifestation of chronic versus host disease. Journal Of Onconephrology 2019

Satyaki Banerjee, MD

  • Case Series of a novel time saving sheathless disruption or central vein stenosis. Accepted as poster presentation at VASA 2022, Vascular Access for Hemodialysis Symposium
  • Dr Banerjee is a speaker at the American Society of Diagnostic and Interventional Nephrology society meeting

Ravi K. Thimmisetty, MD

  • Case report on Nutcracker syndrome: A rare cause of hematuria. Accepted a poster presentation for American Medical Associates Research Challenge, September 2021.
  • Outcome of Donor Derived and Community Acquired West Nile infection in Kidney Transplant recipients. American Transplant Meeting June 2022.

Thilaga Venkatchalman, MD

  • Case report on Nutcracker syndrome: A rare cause of hematuria. Accepted a poster presentation for American Medical Associates Research Challenge, September 2021.